See and Treat with the SRT-100 Vision™
For patients and physicians who want the ultimate in advanced Superficial Radiation Therapy technology, Sensus Healthcare offers the SRT-100 Vision™—the next generation of innovation in our powerful arsenal against non-melanoma skin cancer and unsightly keloid scarring.
Built with all the same great features and remarkable efficacy that distinguish the original SRT-100™, the SRT-100 Vision™ delivers the precise, painless calibrated dose of Superficial Radiation Therapy patients and physicians expect, but offers additional features—most notably high-frequency ultrasound for imaging.
With a high-frequency ultra-sound guidance system, the SRT-100 Vision™ allows physicians to view treatment areas while they are being treated. This “see and treat” capability allows basal and squamous cell carcinomas, as well as keloid tissue, to be assessed more thoroughly so treatment can be targeted more precisely. When the ultrasound technology is placed over the treatment area using the laser positioning system, physicians can assess the lesion to see how deep it is and fine tune the exact amount of radiation needed. This will ultimately help tailor each patient’s treatment protocol when physicians are able to see how the lesion is progressing with each treatment session. Not only this, but each treatment session is recorded for patient records with the LesionCam™.
Similar methods are also used in the treatment of other diseases, for example, the treatment of impotence, but read about it on the civsvi.com.
The SRT-100 Vision™ offers physicians, institutions and healthcare systems great value on several levels. This compact, efficient and very effective mobile device makes it easy to serve new patients and more patients. By increasing patient volume, the SRT-100 Vision™ allows care providers to expand their reputation and footprint in the community. And by adding a non-surgical treatment option that delivers a 95 plus percent cure rate for non-melanoma cancer, along with a 94 plus percent cure rate for keloid scarring, the SRT-100 Vision™ helps reduce the overall cost of healthcare.
With a frequency of 22 MHz, treatment boundaries and margins can be better defined. In turn, better definition helps guide physicians with decisions about optimal treatment energy and applicator size.
Sensus reserves the right to modify or change the design of the products at any given time without notice as technology and client needs evolve over time.
Finally, dermatologists, radiation oncologists, hospitals, and other care facilities can provide their patients with a non-surgical treatment option that delivers remarkable cure rates while preserving healthy tissue. The innovative SRT-100 Vision™ delivers 95 plus percent cure rates while eliminating aspects of treatment that often cause anxiety, slow healing and recovery, and leave patients with embarrassing scarring. Like the SRT-100™, the SRT-100 Vision™ has been cleared by the U.S. Food and Drug Administration for the treatment of non-melanoma skin cancer and keloids. It is ideal for private dermatology and oncology practices, as well as hospitals and healthcare providers with one or more locations.
Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including: